Blueprint for Precision Oligo Discovery

Prediction Made Better: Our modification-aware platform models duplex binding physics to deliver thermodynamic certainty from sequence to therapy.

De-Risking Oligonucleotide Therapeutics with AccuMatch™

Stop guessing binding affinity. AccuMatch™ delivers thermodynamic certainty for modified duplexes, slashing lead optimization timelines and eliminating costly synthesis failures.

Unrivaled Thermodynamic Precision

The Problem: Standard tools fail to accurately predict how chemical modifications (such as LNA, 2OM, 2′-MOE, DHU, 7dA, m6A or PS linkages) alter duplex stability.

The AccuMatch™ Solution: Our AI-powered predictive analytics platform maps exact binding physics across modified sequences, providing true-to-life thermodynamic profiling before you synthesize a single strand.

Accelerated Lead Optimization

The Problem: Traditional trial-and-error in vitro screening drains capital and delays your development pipeline for drugs, vaccines or therapies by months.

The AccuMatch™ Solution: In silico prediction allows you to screen millions of sequences in just minutes instead of months, focusing your wet-lab resources only on candidates with optimal binding kinetics.

Mitigated Off-Target Toxicity

The Problem: Poorly predicted cross-hybridization creates uncertainty with unexpected safety hurdles late in the preclinical development phase.

The AccuMatch™ Solution: Highly sensitive mismatch discrimination maps off-target binding vulnerabilities early, maximizing therapeutic index and safety at the very early stages of the discovery process.from day one.

Patent-Pending Algorithms

For scientists to predict the effect of Locked Nucleic Acids and chemical modifications on CRISPR guide strands, siRNA, and antisense oligonucleotides (ASOs)…or, simply how strongly a chemical gene probe will match its target gene.

Unmet Medical Need

The unmet medical need is gene therapies, gene vaccines, and gene diagnostics for cancer, neurological diseases, hepatological diseases, retinal diseases, and rare genetic disorders.

3.2 Billion Possible Matches

DNA therapy and tests rely on a gene probe, which is a chemical compound that matches a gene. The challenge is that there are almost as many chromosome match locations as there are A, C, G, & T bases, which means 3.2 billion possible matches.

How It Works

Our platform enables scientists to model gene probe sequences, and through our statistical algorithms, to predict the melting temperature of the gene probe, to the gene. Melt temperature is the property most critical to gene probe success.

Every 1.0° Matters

When probe strength is not matched to the gene, efficiency, specificity, and performance degrade quickly.

AccuMatch™ Differentiator

DNA Analytics is the first to improve match strength algorithms in over 20 years. Our best-case improvements are up to 7.0° C, compared to the 1998 landmark study of 0.5° C.